Subscribe To
ADVM / Adverum (ADVM) Completes IND Amendment for Gene Therapy Study
ADVM News
By GlobeNewsWire
May 10, 2023
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish more_horizontal
By GlobeNewsWire
August 26, 2022
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish more_horizontal
By Zacks Investment Research
July 7, 2022
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-a more_horizontal
By Benzinga
July 7, 2022
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
Adverum Biotechnologies Inc (NASDAQ: ADVM) announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinica more_horizontal
By Zacks Investment Research
April 7, 2022
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet A more_horizontal
By GlobeNewsWire
October 9, 2021
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low dose more_horizontal
By GlobeNewsWire
October 9, 2021
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low dose more_horizontal
By GlobeNewsWire
October 9, 2021
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low dose more_horizontal